Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity
A serious adverse effect of cancer therapies is cardiovascular toxicity, which significantly limits the widespread use of antineoplastic agents. The promising new field of cardio-oncology offers the identification of potent anti-cancer therapeutics that effectively inhibit cancer cell proliferation...
Saved in:
Main Authors: | Zoltán Szabó (Author), Lilla Hornyák (Author), Márton Miskei (Author), Lóránt Székvölgyi (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Two novel anticancer compounds with minimum cardiotoxic property
by: Tayebeh Afsharirad, et al.
Published: (2020) -
Enhanced Inhibition of Tumorigenesis Using Combinations of miRNA-Targeted Therapeutics
by: Svetlana Miroshnichenko, et al.
Published: (2019) -
Anticancer Drug-Induced Cardiotoxicity: Insights and Pharmacogenetics
by: Archana Adhikari, et al.
Published: (2021) -
The NRF2, Thioredoxin, and Glutathione System in Tumorigenesis and Anticancer Therapies
by: Morana Jaganjac, et al.
Published: (2020) -
Computational quest, synthesis and anticancer profiling of 3-methyl quinoxaline-2-one-based active hits against the tyrosine kinase
by: Priyadarsini Raj, et al.
Published: (2024)